Paratek Pharma

Paratek Pharmaceuticals, Inc. engages in the development and commercialization of therapies based upon tetracycline chemistry. Its products include omadacycline and sarecycline, which are used for the treatment of community-acquired bacterial infections, including community-acquired bacterial pneumonia, acute bacterial skin and skin structure infections and urinary tract infections. The company was founded by Walter Gilbert and Stuart B. Levy in 1996 and is headquartered in Boston, MA.

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Paratek Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. Paratek's lead product candidate, omadacycline, is a new tetracycline-derived, broad-spectrum antibiotic being developed in both oral tablet and intravenous formulations for use as a first-line monotherapy antibiotic for ABSSSI, CABP, urinary tract infections (UTI) and other serious community-acquired bacterial infections, particularly when antibiotic resistance is of concern to prescribing physicians. Omadacycline has received Qualified Infectious Disease Product (QIDP) designation by the U.S. Food and Drug Administration for both the oral and intravenous formulations in all three of these infectious disease categories. Paratek has Special Protocol Assessment agreements with the FDA for the phase 3 trials planned in ABSSSI and CABP.

Paratek Plods Along

Paratek Pharmaceuticals, Inc. (PRTK) CEO Evan Loh on Q1 2020 Results - Earnings Call Transcript

Paratek (PRTK) delivered earnings and revenue surprises of 20.48% and 2.15%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Paratek Pharmaceuticals (PRTK) Reports Q1 Loss, Tops Revenue Estimates

As of late, it has definitely been a great time to be an investor Paratek Pharmaceuticals

Will Paratek Pharmaceuticals Continue to Surge Higher?

Purchase of the first 2,500 treatment courses of NUZYRA expected in the first half of 2020 Purchase of the first 2,500 treatment courses of NUZYRA expected in the first half of 2020

Paratek Pharmaceuticals Announces the Submission of the pre-Emergency Use Authorization Application to the FDA for NUZYRA• (omadacycline)

Paratek Revenue Ramp-Up Is Underappreciated By The Market And Should Drive Stock Price Gains

Paratek Pharmaceuticals: A Bright 2020 Ahead

Paratek Pharmaceuticals, Inc. (PRTK) CEO Evan Loh on Q4 2019 Results - Earnings Call Transcript

BOSTON, Feb.  24, 2020  (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced the Company has entered into a license grant with Almirall (ALM) for SEYSARA® (sarecycline) for the greater China region, which includes the Peoples Republic of China, Hong Kong, and Macau.  Under the terms of the agreement, Paratek will earn high single-digit royalties on net sales in the greater China region.  Almirall plans to develop sarecycline for acne in China, with a potential submission to the China National Medical Products Administration in 2023.  Almirall also has rights to SEYSARA for acne in the U.S. and has successfully commercialized the product since its launch in January 2019.  

Paratek Announces License Grant to Almirall for SEYSARA® (sarecycline) for Greater China Region

Paratek Pharmaceuticals: The Best Bet In A Bad Space

Antero Midstream Partners

Clovis Oncology

Callon Petroleum

Gerdau

Find Cheap Highly-Ranked Stocks Trading Under $10 for 2020

Investors need to pay close attention to Paratek Pharmaceuticals (PRTK) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Paratek Pharmaceuticals (PRTK) Stock?

When stocks rally almost 40% in a single trading session, it tends to draw some new attention.

Why One Analyst Still Sees Almost 200% Upside in Paratek Pharma, Even After Its Huge Gain

Some government contracts can make or break companies that supply or offer services to the government.

BioShield/Anthrax Contract Sets Solid Stage for Paratek Pharmaceuticals in 2020

Shares of Paratek Pharmaceuticals Inc. PRTK, -4.84% jumped 42% in premarket trading on Thursday on heavy volume after the company said it was awarded a five-year government contract worth up to $169 million to support the development of Nuzyra as a treatment and prophylaxis for anthrax.

Paratek's stock rockets on government contract

- Total award valued at up to $285 million 

Paratek Awarded BARDA Project BioShield Contract for NUZYRA®

Akcea Therapeutics

AMAG Pharmaceuticals

Axsome Therapeutics

Cronos Group

Eidos Therapeutics Inc

Heron Therapeutics

Ligand Pharmaceuticals

PolarityTE Inc

Viking Therapeutics

Intrexon

ZIOPHARM Oncology

Biotech investment is risk fraught. Most biotech stocks are at the mercy of binary events, which serve as make-or-break catalysts.

12 Biotech Stocks Primed For A Short Squeeze

BOSTON, Dec.  02, 2019  (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced that on November 29, 2019, the Company granted stock options and restricted stock units to one new employee of the Company. These awards were granted pursuant to the Paratek Pharmaceuticals, Inc. 2017 Inducement Plan, as amended, which was approved by the Company's board of directors on June 15, 2017, under Rule 5635(c)(4) of the NASDAQ Listing Rules, for equity grants to employees entering into employment or returning to employment after a bona fide period of non-employment with the Company, as an inducement material to such individuals entering into employment with the Company.

Paratek Announces  Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Almaden Minerals

Ambev

Babcock & Wilcox Enterprises

Geron

Synacor

While trade relations and tax-loss selling are causes for concern, opportunities for short-term and swing traders remain abundant.

Penny Stocks to Buy Using Technical Analysis for December 2019

Paratek Pharmaceuticals, Inc. (PRTK) CEO Evan Loh on Q3 2019 Results - Earnings Call Transcript

Paratek (PRTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Paratek Pharmaceuticals (PRTK) to Report a Decline in Earnings: What to Look Out for

BOSTON, Oct.  31, 2019  (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, announced the outcome of its two exploratory Phase 2 clinical studies evaluating the efficacy and safety of its once-daily oral and intravenous (IV) modernized tetracycline omadacycline in patients with two common forms of urinary tract infections (UTI).

Paratek Announces Top Line Results of Phase 2 Clinical Studies of Omadacycline in Urinary Tract Infections

BOSTON, Oct.  17, 2019  (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, announced today that the company has withdrawn its submission to the European Medicines Agency (EMA) of the Marketing Authorization Application (MAA) for NUZYRA® (omadacycline).   

Paratek Withdraws European Marketing Authorization Application for Oral and Intravenous NUZYRA in Skin Infections and Pneumonia

BOSTON, Oct.  01, 2019  (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced that on September 30, 2019, the Company granted stock options and restricted stock units to two new employees of the Company. These awards were granted pursuant to the Paratek Pharmaceuticals, Inc. 2017 Inducement Plan, as amended, which was approved by the Company's board of directors on June 15, 2017, under Rule 5635(c)(4) of the NASDAQ Listing Rules, for equity grants to employees entering into employment or returning to employment after a bona fide period of non-employment with the Company, as an inducement material to such individuals entering into employment with the Company.

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4).

Data highlight Paratek’s commitment to further understanding safety and efficacy of NUZYRA® (omadacycline) in unique population subsets Data highlight Paratek’s commitment to further understanding safety and efficacy of NUZYRA® (omadacycline) in unique population subsets

News for Paratek Pharma Stock (PRTK)